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Abstract 
The benefit or risk of sodium-glucose cotransporter 2 (SGLT2) inhibitors on 
cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (T2DM) has not 
been established. We aimed to assess the comparative CV safety and mortality risk 
associated with the use of SGLT2 inhibitors. PubMed, EMBASE, CENTRAL and 
ClinicalTrials.gov were systematically searched up to January 27, 2016 to identify 
randomized controlled trials (RCTs) with the use of SGLT2 inhibitors of at least 24 
weeks’ duration. The primary outcomes included all-cause mortality and major adverse 
cardiovascular events (MACE). A random-effects network meta-analysis was performed 
to calculate the odds ratio (OR) with 95% confidence interval (CI). We identified 37 
eligible trials involving 29,859 patients that compared three SGLT2 inhibitors 
(canagliflozin, dapagliflozin, and empagliflozin) to placebo and other active antidiabetic 
treatments. Of all direct and indirect comparisons, only empagliflozin compared with 
placebo was significantly associated with lower risk of all-cause mortality (OR, 0.67; 95% 
CI 0.56 to 0.81) and MACE (OR, 0.81; 95% CI 0.70 to 0.93). However, the significant 
effect of empagliflozin was largely driven by one large randomized trial (EMPA-REG 
OUTCOME trial). Neither dapagliflozin nor canagliflozin was significantly associated with 
any harm. In conclusion, current RCT evidence suggests that three common SGLT2 
inhibitors are not associated with increased risk of all-cause mortality and CV outcomes 
when used to treat T2DM patients. Though empagliflozin may have a protective effect, 
further confirmative data from rigorous RCTs are needed.  
Keywords: SGLT2 inhibitors, type 2 diabetes, cardiovascular events, mortality, 
meta-analysis 
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   Sodium glucose cotransporter 2 (SGLT2) inhibitors are a novel class of 
glucose-lowering agents for treating type 2 diabetes mellitus (T2DM), which act insulin 
independent to selectively inhibit renal glucose reabsorption, thereby increasing urinary 
glucose excretion1. SGLT2 inhibitors have the potential to improve cardiovascular (CV) 
risk profiles (e.g., lower blood pressure and weight loss) 2. In 2008, the U.S. Food and 
Drug Administration (FDA) required a careful CV safety assessment for all novel 
glucose-lowering agents 3. Recently, one large rigorously conducted clinical trial 
(EMPA-REG OUTCOME trial) found that patients with T2DM at high risk for CV events 
achieved a CV benefit from empagliflozin as compared with placebo 4. However, despite 
such intriguing results, it remains uncertain whether the CV benefits are attributable 
specifically to empagliflozin alone or represent a class effect 5. By contrast to 
conventional pairwise meta-analysis comparing only two interventions (A vs. B), a 
network meta-analysis is a useful method for comparing multiple interventions (A vs. B 
vs. C vs. …) , as it analyzed simultaneously both direct comparisons of interventions 
within randomized controlled trials (RCTs) and indirect comparisons across trials 
referred to a common comparator (e.g., placebo) 6. We therefore conducted a network 
meta-analysis of all available RCTs to comprehensively assess the comparative effects 
of SGLT2 inhibitors on CV safety and mortality and clarify whether potential effects on 
CV outcomes are a specific drug effect or a class effect. 
Methods 
   This review was performed according to the PRISMA extension statement for 
reporting of systematic reviews incorporating network meta-analyses of health care 
interventions 7 and was registered with PROSPERO (number, CRD42015026853). 
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   An electronic search was performed in PubMed, Embase, and Cochrane Central 
Register of Controlled Trials (CENTRAL) through January 27, 2016 to identify eligible 
RCTs with a combination of relevant search terms (Supplementary Table 1). No 
limitations of language and year of publication were applied. Additional data from the 
reference lists of relevant reviews and ClinicalTrials.gov were further searched to ensure 
identification of published and unpublished trials.  
   Eligible trials met the following criteria: 1) RCTs with follow-up duration at least 24 
weeks; 2) Adults (>18 years of age) with T2DM; 3) SGLT2 inhibitors with any licensed 
dose used as monotherapy or in combination with other antidiabetic drugs compared 
with placebo, another SGLT2 inhibitor, or other active antidiabetic treatments; and 4) At 
least one of our selected CV outcomes was reported in the published article, or the 
results were presented on ClinicalTrials.gov. Our primary outcomes included all-cause 
mortality and major adverse cardiovascular events (MACE), including death from 
cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The secondary 
outcomes included heart failure or heart failure requiring hospitalization, unstable angina 
or unstable angina requiring hospitalization, atrial fibrillation, and transient ischemic 
attack. The CV events were reported by investigators as an adverse event (or serious 
adverse event) identified in the database using pre-specified lists from the Medical 
Dictionary for Regulatory Activities (MedDRA). 
   Two reviewers independently selected the studies and extracted relevant information 
about trial characteristics and outcomes. If multiple reports from the same trial were 
retrieved, only the most complete and/or longest follow-up data were used. If CV events 
were not reported in the manuscript, data from the “Serious Adverse Events” section on 
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the ClinicalTrials.gov were extracted. In addition, if specific CV events were not reported 
on ClinicalTrials.gov, the incidence of the events was assumed to be zero. If two different 
groups of randomization of non-overlapping patient groups (e.g., A vs B and C vs D) 
were included in the same report, each group was considered separately. If three arms 
(e.g., A vs B vs A+B) were evaluated in the RCTs, data from only two arms (A vs B) were 
included. When placebo was switched to an active comparator in the extended period of 
trials, only the period with placebo was documented. In addition, two reviewers 
independently critically assessed all included RCTs according to the modified Cochrane 
risk of bias tool, which is described in the Cochrane Collaboration's tool for assessing 
risk of bias 8. If any data were unclear or missing, the authors of the original RCTs were 
contacted for further information. Any disagreements were resolved by consensus or by 
discussion with a third reviewer. 
   Pairwise and network meta-analyses were conducted to calculate odds ratios (ORs) 
with 95% confidence intervals (CIs) for the primary and secondary outcomes.  
For pairwise meta-analyses, a Peto OR was calculated for the effect sizes from direct 
comparisons because of very low event rate 9. An I² statistic was used to evaluate the 
presence of heterogeneity within meta-analyses, with I2 of 25%, 50%, and 75% indicating 
a low, moderate, and high level of evidence of statistical heterogeneity, respectively.  
   For indirect and mixed comparisons, a network meta-analysis with a random-effects 
model was performed to compare different SGLT2 inhibitors. For zero-event RCT, a 0.5 
zero-cell correction was applied before meta-analysis10. The network meta-analysis was 
performed with STATA version 14 using the “mvmeta” command and programmed 
STATA routines 11,12. To rank the SGLT2 inhibitors for a specified outcome, we estimated 
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the relative ranking probability of each treatment using surface under the cumulative 
ranking curve (SUCRA) and mean ranks. For all-cause mortality and CV outcomes, 
higher SUCRA score and lower mean rank indicate a safer intervention13. In addition, a 
clustered ranking plot of the network was performed to group the treatments based on 
the SUCRA probabilities for MACE and any-cause mortality. The heterogeneity variance 
(tau) was used to estimate the extent of between-study heterogeneity14.  
   To check for the presence of inconsistency, a loop inconsistency–specific approach 
was introduced to evaluate the difference between direct and indirect estimates for a 
specific comparison 15. To check the assumption of consistency in the entire network, a 
design-by-treatment interaction model using the χ2 test was used 16. Otherwise, to 
investigate the robustness of the findings, we assessed the effect of differing trial and 
participant characteristics on the primary outcomes in sensitivity analyses by restricting 
to trials with follow-up at least 52 weeks, white patients, SGLT2 inhibitors combination 
therapy, and trials without pre-specified CV events as primary outcomes. In addition, 
when primary outcomes with any SGLT2 inhibitor detected a significant difference, a 
cumulative meta-analysis was conducted to assess the robustness of evidence over 
time17. Finally, a comparison-adjusted funnel plot was used to assess small study effects 
within a network of interventions 18.  
Results 
   A total of 1,268 citations were retrieved through electronic search, from which 172 
potentially eligible reports were identified by reviewing study titles and abstracts. Finally, 
37 eligible RCTs involving 28,859 patients were included in this meta-analysis (Figure 1). 
These patients were randomly assigned to a SGLT2 inhibitor (canagliflozin, dapagliflozin, 
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or empagliflozin) or control groups (placebo or other active anti-diabetic treatments). 
Sample sizes of individual trials ranged between 180 and 7,020 participants, and the 
periods of follow-up ranged from 24 to 160 weeks. Of all the trials, only three included 
patients with pre-existing CV disease (more than 90%) 4,19,20. One extension trial 
provided two independent RCT datasets for two different comparisons (empagliflozin 
versus metformin and empagliflozin versus sitagliptin), which we considered separately 
21. The data of two trials were presented together on ClinicalTrials.gov, so we included 
the combined data as one trial 22,23. Detailed information is presented in the 
Supplementary Table 2. 
   Quality assessment of the 37 RCTs is summarized as follows: 30 RCTs reported 
adequate random sequence generation, and 26 RCTs reported adequate allocation 
concealment. Masking conditions were high in two RCTs, which were both "open label" 
in their extended periods. In addition, only one RCT pre-specified CV events as primary 
outcomes, and none of the studies had incomplete outcome data (Supplementary 
Figure 1). All of the trials were funded by industry. Moreover, the comparison-adjusted 
funnel plot showed no small study effects for the primary outcomes of interest 
(Supplementary Figure 2). 
   Networks of eligible comparisons for the primary outcomes are presented in Figure 2, 
and the results for direct comparisons and network estimates are presented in the 
appendix (Supplementary Tables 3-5 and Supplementary Figures 3-8). The results of 
our pairwise meta-analysis were consistent with the results of our network meta-analysis. 
In the network meta-analyses, low statistical heterogeneity was observed in networks 
(tau≈0). No loop inconsistency was detected in the loop of comparisons between direct 
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and indirect evidence (all 95%CIs across zero). In addition, no global inconsistency was 
detected within any network (all P>0.05) (Supplementary Tables 6-7).  
   Among the 37 trials selected, 34 (involving 26,565 patients with 1,016 events) 
provided adequate data for MACE outcomes. Empagliflozin was significantly associated 
with a lower risk of MACE than placebo (OR, 0.81; 95% CI, 0.70 to 0.93), but there was 
no significant difference between dapagliflozin (OR, 0.81; 95%CI, 0.46 to 1.45) or 
canagliflozin (OR, 1.10; 95%CI, 0.53 to 2.29) and placebo (Figure 3). Similar rates of 
MACE were found among these three SGLT2 inhibitors (Supplementary Figure 3). 
All-cause mortality was reported in all 37 trials (28,859 patients with 537 events). Only 
empagliflozin was significantly better at reducing all-cause mortality than placebo (OR, 
0.67; 95%CI, 0.56 to 0.81), and there were no significant differences between the other 
two SGLT2 inhibitors and placebo (canagliflozin: OR, 0.85; 95%CI, 0.36 to 2.05; 
dapagliflozin: OR, 1.12; 95%CI, 0.51 to 2.44) (Figure 3). There was no significant 
difference between these three SGLT2 inhibitors (Supplementary Figure 4). A 
clustered ranking plot based on SUCRA probabilities suggests that empagliflozin 
appeared to reduce risk of MACE and any-cause mortality more than the other two 
SGLT2 inhibitors (Figure 4 and Supplementary Table 8). 
   In terms of heart failure or heart failure requiring hospitalization, only empagliflozin 
was associated with lower incidence than placebo (OR, 0.65; 95%CI, 0.50 to 0.84); the 
other two SGLT2 inhibitors had no effects on this outcome (dapagliflozin: OR, 0.60; 
95%CI, 0.27 to 1.33; canagliflozin: OR, 0.68; 95%CI, 0.22 to 2.06) (Figure 3). The risk of 
heart failure or heart failure requiring hospitalization was similar between these three 
SGLT2 inhibitors (Supplementary Figure 5). SGLT2 inhibitors were generally similar to 
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placebo for risks of unstable angina or unstable angina requiring hospitalization, atrial 
fibrillation, and transient ischemic attack (Figure 3). There was no significant difference 
in these events between these SGLT2 inhibitors. (Supplementary Figure 6-8). 
   In the sensitivity analyses restricting to trials with follow-up of at least 52 weeks (22 
RCTs), white patients (34 RCTs), and SGLT2 inhibitors in combination with other active 
antidiabetic drugs (24 RCTs), the results were unchanged. However, the significant 
results of empagliflozin for MACE and all-cause mortality outcomes in complete analysis 
were largely driven by the EMPA-REG OUTCOME trial, which used CV outcomes as 
primary outcomes 4. MACE (OR, 0.70; 95%CI, 0.41 to1.19) and all-cause mortality (OR, 
0.70; 95%CI, 0.29 to1.70) for empagliflozin were not significantly different from those 
associated with placebo when we restricted to the trials without pre-specified CV 
outcomes as primary outcomes (excluding EMPA-REG OUTCOME trial). A cumulative 
meta-analysis by publication year of trials showed that empagliflozin was significantly 
associated with a reduced risk for primary outcomes since 2015 when the trial was 
published by Zinman et al in 2015 (Supplementary Figure 9) 4. It also indicated that the 
significant CV benefit of empagliflozin was largely driven by the EMPA-REG OUTCOME 
trial. 
Discussion 
   Our network meta-analysis of all eligible RCTs involving 30,250 patients showed that 
none of the three SGLT2 inhibitors was harmful for CV outcomes or all-cause mortality. 
For the primary outcomes, only empagliflozin appeared associated with a lower risk of 
MACE and all-cause mortality compared to placebo, whereas neither dapagliflozin nor 
canagliflozin was significantly associated with any harm. With respect to secondary 
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outcomes, only empagliflozin had lower risk of heart failure or heart failure requiring 
hospitalization than placebo, and all three SGLT2 inhibitors had similar risk of unstable 
angina or unstable angina requiring hospitalization, atrial fibrillation, and transient 
ischemic attack. However, the protective effect of MACE and all-cause mortality from 
empagliflozin was largely driven by the EMPA-REG OUTCOME trial. Our findings 
regarding the CV benefits of empagliflozin should be interpreted cautiously. Further 
evidence from trials using primary CV outcomes is needed to confirm these results. 
   Our findings from pairwise and network meta-analyses showed that SGLT2 inhibitors 
were not associated with any increased risk of all-cause mortality and CV outcomes, and 
only empagliflozin showed a CV protective benefit, which was consistent with two 
meta-analyses 24,25. The potential effect of glucose-lowering agents on CV events might 
depend on how their differing modes of action modulate CV risk factors 26. Unlike other 
glucose-lowering agents, SGLT2 inhibitors offer an insulin-independent mechanism of 
action by selectively inhibiting renal glucose reabsorption to increase urinary glucose 
excretion1. Thus, SGLT2 inhibitors possibly improve a variety of CV risk factors 26. 
Evidence from meta-analyses and clinical trials has shown that SGLT2 inhibitors could 
meaningfully reduce blood pressure and weight 27. Interestingly, data showed that 
empagliflozin could also reduce arterial stiffness 28, which is a strong independent 
predictor of CV events and death 29. In addition, SGLT2 inhibitors could reduce total fat 
mass and regional adipose tissue distribution, which are both associated with CV 
complications 30. However, the precise mechanisms underlying the CV benefits of 
SGLT2 inhibitors are still unclear.  
11	
	
   Of the SGLT2 inhibitors, our meta-analysis provided evidence for a reduction in 
MACE and all-cause mortality by empagliflozin only. Indeed, the findings from the first 
main CV outcomes research (EMPA-REG OUTCOME trial) of empagliflozin in patients 
with high risk of CV disease contributed predominantly to our results, and no significant 
difference between empagliflozin and placebo remained after excluding this trial, which 
comprised more than about 84% percent of events (MACE with 853 events and 1,016 
events from this trial and all trials, respectively) 4. The conflicting results might be caused 
by the fact that more non-serious CV events were recorded in EMPA-REG OUTCOME 
trial, but only rare serious or fatal CV events were reported in most of the phase II and III 
RCTs, yielding low sample size/power to detect a statistical difference in these small 
RCTs, even in the meta-analysis. Therefore it is not surprising that there was no 
significant difference between the other two SGLT2 inhibitors (dapagliflozin and 
canagliflozin) and placebos in terms of MACE and all-cause mortality, which was 
consistent with three pairwise meta-analyses 2,24,27. Two meta-analyses showed that the 
combined SGLT-2 inhibitor group (mainly dapagliflozin and canagliflozin) was not 
significantly associated with an reduced risk for MACE compared with placebo or active 
treatments2 27, and one meta-analysis indicated that canagliflozin and dapagliflozin did 
not significantly affect mortality or CV outcomes24. However, one meta-analysis found a 
lower risk of MACE from dapagliflozin than control 25. The CV safety of dapagliflozin and 
canagliflozin needed to be explored further, due to current evidence from small-scale, 
short-term RCTs without pre-specified CV outcomes as primary outcomes. Therefore, to 
address the CV safety issue, in addition to the EMPA-REG OUTCOME trial, several 
large RCTs using CV events as primary outcomes are still ongoing, including CANVAS, 
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CANVAS-R, DECLARE-TIMI58, and CREDENCE. In future these large outcome studies 
will not only provide enough statistical power to confirm our findings, but also solve the 
issue of whether SGLT2 inhibitors offer a specific drug effect or a class effect in terms of 
CV benefits. 
   Consistent with the findings of the EMPA-REG OUTCOME trial, empagliflozin was 
the only SGLT2 inhibitor to reduce the risk of heart failure or heart failure requiring 
hospitalization, compared with placebo. However, there was a trend toward reduced risk 
of heart failure with the use of dapagliflozin or canagliflozin. The protective effect of 
SGLT2 inhibitors (mainly empagliflozin) against heart failure is possibly attributable to 
improvements in CV risk factors. SGLT2 inhibitors were not associated with increased 
risk for unstable angina or unstable angina requiring hospitalization, atrial fibrillation, or 
transient ischemic attack. However, these findings need to be confirmed in future 
outcome research studies with adequate power. 
   Compared with two previous meta-analyses24,25, our comprehensive network 
meta-analysis has two major strengths. First, network meta-analysis was introduced to 
simultaneous analysis of both direct and indirect comparisons to provide evidence of 
comparative effects among SGLT2 inhibitors. Secondly, sensitivity and cumulative 
meta-analyses were conducted to test the evidence sufficiency and finding robustness.  
   However, some limitations of our study merit further discussion. First, a major 
limitation was that few RCTs of SGLT2 inhibitors include CV outcomes as primary 
outcomes. Thus, one of the domains of risk of bias (pre-specified CV outcomes as 
adverse event of interest) was judged as high. Secondly, only rare serious or fatal CV 
events (often zero events) were reported in the phase II or III clinical trials, which 
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resulted in a low statistical power to calculate the exact incidence of some CV event, 
which might also partly explain the majority of CV cases from the EMPA-REG 
OUTCOME trial. Thirdly, the network meta-analysis model was based on the assumption 
that patient characteristics from selected trials were sufficiently similar (e.g., trials 
comparing canagliflozin with placebo were similar to trials comparing dapagliflozin with 
placebo in terms of CV risk factors at baseline). Varied background treatments and 
patients’ characteristics among the RCTs might contribute to clinical heterogeneity, 
though low statistical heterogeneity and absence of inconsistency of our network model 
were detected in the network meta-analysis. Fourthly, different types of active 
comparators were combined into a control group to increase the power, but might 
contribute to heterogeneity. Finally, due to the fact that no trials of newer SGLT2 
inhibitors (such as ipragliflozin, ertugliflozin, remogliflozin, luseogliflozin, tofogliflozin, or 
sotagliflozin) were included, the CV outcomes for these agents remain uncertain.  
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Figure Legends:                               
Figure 1. Flow chart of the identification of eligible trials. 
 
Figure 2. Network of available SGLT2 inhibitor comparisons for MACE (left) and 
all-cause mortality (right). The size of the nodes corresponds to the number of trials 
including respective treatments. The directly compared treatments are linked with a line, 
the thickness of which corresponds to the number of trials that assessed this comparison. 
CANA = canagliflozin; DAPA = dapagliflozin; EMPA = empagliflozin; PLA = placebo; 
ACT = active treatments. 
 
Figure 3. Network meta-analysis of SGLT2 inhibitor compared with placebo on primary 
and secondary outcomes. Common heterogeneity for every outcome in the network 
meta-analysis was low (tau≈0). Treatments are ranked by SUCRA values. MACE = 
major adverse cardiovascular events; CANA = canagliflozin; DAPA = dapagliflozin; 
EMPA = empagliflozin; PLA = placebo; ACT = active treatments.  
 
Figure 4. Clustered ranking plot of the network based on the SUCRA probabilities for 
MACE and any-cause mortality. Each symbol represents a group of treatments that 
belong to the same cluster. Treatments lying in the upper right corner are considered to 
be safer than the other treatments for both outcomes. MACE = major adverse 
cardiovascular events; CANA = canagliflozin; DAPA = dapagliflozin; EMPA = 
empagliflozin; PLA = placebo; ACT = active treatments. 
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Table 1 Sensitivity analyses for the odds ratios with 95% confidence interval and rank order of MACE and all-cause 
mortality 
Treatments Complete 
analysis 
SUCR
A rank 
Follow-up 
periods ≥ 
52 weeks 
SUCR
A rank 
White 
patients 
SUCR
A 
rank 
Non-pre- 
specified 
CV 
outcomesa 
SUCR
A 
rank 
SGLT2 
inhibitors 
combinatio
n therapy 
SUCRA 
rank 
MACE 
DAPA 0.81 
(0.46, 1.45) 
2 0.76 
(0.34, 1.72)
2 0.83 
(0.47,1.48) 
2 0.80 
(0.45, 1.43) 
2 0.88 
(0.48, 1.61) 
2 
EMPA 0.81 
(0.70, 0.93) 
1 0.81 
(0.70, 0.93)
1 0.81 
(0.70,0.94) 
1 0.70 
(0.41, 1.19) 
1 0.81 
(0.70, 0.93) 
1 
CANA 1.10 
(0.53, 2.29) 
3 1.27 
(0.57, 2.82)
3 1.18 
(0.56,2.48) 
3 1.03 
(0.48, 2.22) 
3 1.30 
(0.60, 2.82) 
3 
ACT 1.37 
(0.78, 2.43) 
4 1.45 
(0.80, 2.63)
4 1.56 
(0.86,2.81) 
4 1.24 
(0.64, 2.42) 
4 1.66 
(0.90, 3.04) 
4 
Heterogeneit
y (tau) 
≈0 
Low 
 ≈0 
Low 
 ≈0 
Low 
 ≈0 
Low 
 ≈0 
Low 
 
All-cause mortality 
DAPA 1.12 
(0.51, 2.44) 
3 1.35 
(0.42, 4.31)
3 1.10 
(0.50,2.41) 
4 1.12 
(0.51, 2.46) 
3 1.30 
(0.56, 2.99) 
4 
EMPA 0.67 
(0.56, 0.81) 
1 0.67 
(0.56, 0.81)
1 0.67 
(0.55,0.81) 
1 0.70 
(0.29, 1.70) 
1 0.67 
(0.56, 0.81) 
1 
CANA 0.85 
(0.36, 2.05) 
2 1.07 
(0.37, 3.14)
2 0.82 
(0.34,2.00) 
2 0.86 
(0.35, 2.12) 
2 0.94 
(0.36, 2.44) 
2 
ACT 1.11 
(0.52, 2.34) 
4 1.07 
(0.47, 2.42)
4 1.02 
(0.45,2.30) 
3 1.13 
(0.46, 2.76) 
4 0.93 
(0.39, 2.18) 
3 
Heterogeneit
y (tau) 
≈0 
Low 
 ≈0 
Low 
 ≈0 
Low 
 ≈0 
Low 
 ≈0 
Low 
 
aExcluded the main CV outcome study (EMPA-REG OUTCOME trial).  
MACE = major adverse cardiovascular events; SUCRA = surface under the cumulative ranking; SGLT2 = sodium glucose 
cotransporter 2; CV = cardiovascular; CANA = canagliflozin; DAPA = dapagliflozin; EMPA = empagliflozin; PLA = placebo; 
ACT = active treatments. 
